Annovis Bio Appoints Matthew Peterson, Ph.D., as Senior Clinical Scientist
Annovis Bio (NYSE: ANVS) has appointed Matthew Peterson, Ph.D., as Senior Clinical Scientist to oversee medical, ethical, and scientific quality of the company's clinical trials. Peterson joins with experience from Axogen, Ethicon, Exactech, and the Department of Veterans Affairs. His appointment comes as Annovis approaches initiation of pivotal Phase 3 studies. Peterson holds a Ph.D. in Biomedical Engineering from the University of Florida and will contribute to the clinical development of buntanetap for neurodegenerative diseases like Alzheimer's and Parkinson's.
Annovis Bio (NYSE: ANVS) ha nominato Matthew Peterson, Ph.D., come Senior Clinical Scientist per supervisionare la qualità medica, etica e scientifica degli studi clinici della società. Peterson porta con sé un'esperienza da Axogen, Ethicon, Exactech e il Dipartimento dei Veterani. La sua nomina arriva mentre Annovis si prepara all'avvio dei preziosi studi di Fase 3. Peterson ha conseguito un dottorato in Ingegneria Biomedica presso l'Università della Florida e contribuirà allo sviluppo clinico di buntanetap per le malattie neurodegenerative come l'Alzheimer e il Parkinson.
Annovis Bio (NYSE: ANVS) ha nombrado a Matthew Peterson, Ph.D., como Científico Clínico Senior para supervisar la calidad médica, ética y científica de los ensayos clínicos de la empresa. Peterson se une tras su experiencia en Axogen, Ethicon, Exactech y el Departamento de Asuntos de Veteranos. Su nombramiento se produce a medida que Annovis se acerca a la iniciación de los estudios fundamentales de Fase 3. Peterson tiene un doctorado en Ingeniería Biomédica de la Universidad de Florida y contribuirá al desarrollo clínico de buntanetap para las enfermedades neurodegenerativas como el Alzheimer y el Parkinson.
안노비스 바이오 (NYSE: ANVS)는 매튜 피터슨, 박사를 수석 임상 과학자로 임명하여 회사의 임상 시험에서 의학적, 윤리적 및 과학적 품질을 감독하도록 했습니다. 피터슨은 Axogen, Ethicon, Exactech 및 재향군인부에서의 경험을 가지고 있습니다. 그의 임명은 안노비스가 중요한 3상 연구를 시작하려 할 때 이루어졌습니다. 피터슨은 플로리다 대학교에서 생체의학 공학 박사 학위를 보유하고 있으며, 알츠하이머 및 파킨슨병과 같은 신경퇴행성 질환을 위한 buntanetap의 임상 개발에 기여할 것입니다.
Annovis Bio (NYSE: ANVS) a nommé Matthew Peterson, Ph.D., au poste de Scientifique Clinique Senior pour superviser la qualité médicale, éthique et scientifique des essais cliniques de l'entreprise. Peterson rejoint l'équipe avec une expérience d'Axogen, Ethicon, Exactech et du Département des Anciens Combattants. Sa nomination intervient alors qu'Annovis se prépare à l'initiation des études pivots de Phase 3. Peterson détient un doctorat en ingénierie biomédicale de l'Université de Floride et contribuera au développement clinique du buntanetap pour les maladies neurodégénératives telles que la maladie d'Alzheimer et la maladie de Parkinson.
Annovis Bio (NYSE: ANVS) hat Matthew Peterson, Ph.D., zum Senior Clinical Scientist ernannt, um die medizinische, ethische und wissenschaftliche Qualität der klinischen Studien des Unternehmens zu überwachen. Peterson bringt Erfahrung aus Axogen, Ethicon, Exactech und dem Ministerium für Veteranenangelegenheiten mit. Seine Ernennung erfolgt, während Annovis sich auf den Beginn der entscheidenden Phase-3-Studien vorbereitet. Peterson hat einen Doktortitel in Biomedizintechnik von der Universität Florida und wird zur klinischen Entwicklung von buntanetap für neurodegenerative Erkrankungen wie Alzheimer und Parkinson beitragen.
- Strategic timing of hire coincides with upcoming Phase 3 trials initiation
- Addition of experienced clinical research professional strengthens R&D team
- None.
MALVERN, Pa., Nov. 07, 2024 (GLOBE NEWSWIRE) -- via IBN -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company developing transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced the appointment of Matthew Peterson, Ph.D., as Senior Clinical Scientist. Dr. Peterson will be responsible for medical, ethical, and scientific quality and rigor in the initiation, conduct, reporting, and successful completion of Annovis’ clinical trials.
"We are thrilled to welcome Matthew Peterson to our team," said Cheng Fang, Ph.D., Senior Vice President, Research and Development, at Annovis. "Dr. Peterson brings an impressive track record in clinical research and a passion for improving patient outcomes, joining us at a crucial moment as we are approaching initiation of pivotal Phase 3 studies.”
Dr. Peterson joins Annovis with experience in both academic research and the life sciences industry. Most recently, he served as Senior Clinical Research Science Manager at Axogen, where he focused on therapies for peripheral nerve repair and regeneration. His previous roles include Clinical Research Scientist Contractor at Ethicon and Senior Clinical Project Manager at Exactech, along with a decade-long tenure at the Department of Veterans Affairs (VA). During his time at the VA, Dr. Peterson led studies on pressure ulcer prevention, fall risk assessment, and interventions to improve the quality of life for veterans with spinal cord injuries and other conditions. Dr. Peterson holds a Ph.D. in Biomedical Engineering from the University of Florida, where he specialized in developing technologies aimed at reducing clinical complications for vulnerable patient populations. He has authored numerous peer-reviewed publications and served as a principal investigator on studies funded by organizations including the Department of Defense and the VA.
"I am excited to join Annovis and to work alongside such a dedicated team at this pivotal moment for the company," said Dr. Peterson. "I look forward to contributing to the clinical development of buntanetap and supporting the company’s goal of bringing transformative therapies to patients affected by neurodegenerative diseases."
About Annovis Bio
Headquartered in Malvern, Pennsylvania, Annovis Bio is dedicated to addressing neurodegeneration in diseases such as AD and PD. The company’s innovative approach targets multiple neurotoxic proteins, aiming to restore brain function and improve the quality of life for patients. For more information, visit www.annovisbio.com and follow us on LinkedIn, YouTube, and X.
Investor Alerts
Interested investors and shareholders are encouraged to sign up for press releases and industry updates by registering for Email Alerts at https://www.annovisbio.com/email-alerts. Additionally, we invite you to explore our updated investor website, which provides comprehensive access to company news, financial reports, and other key information.
Forward-Looking Statements
This press release contains "forward-looking" statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements include, but are not limited to, the Company's plans related to clinical trials. Forward-looking statements are based on current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Such risks and uncertainties include, but are not limited to, those related to patient enrollment, the effectiveness of Buntanetap, and the timing, effectiveness, and anticipated results of the Company's clinical trials evaluating the efficacy, safety, and tolerability of Buntanetap. Additional risk factors are detailed in the Company's periodic filings with the SEC, including those listed in the "Risk Factors" section of the Company's Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. All forward-looking statements in this press release are based on information available to the Company as of the date of this release. The Company expressly disclaims any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law.
Contact Information:
Annovis Bio Inc.
101 Lindenwood Drive
Suite 225
Malvern, PA 19355
www.annovisbio.com
Investor Contact:
Scott McGowan
InvestorBrandNetwork (IBN)
Phone: 310.299.1717
www.annovisbio.com/investors-relations
IR@annovisbio.com
FAQ
What is Matthew Peterson's role at Annovis Bio (ANVS)?
What stage is Annovis Bio (ANVS) at with their clinical trials?
What diseases is Annovis Bio (ANVS) targeting with their therapies?
What is the name of Annovis Bio's (ANVS) drug candidate?
